SlideShare una empresa de Scribd logo
1 de 20
The Orphan Drug Act Jeff W. Bailey MS Senior Regional Business Manager Shire Human Genetic Therapies June 2009
References/Data Source ,[object Object],[object Object],[object Object],[object Object]
Table of Contents ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
The Orphan Drug Act ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Provisions of the Orphan Drug Act: ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Governmental Entities Implementing the Orphan Drug Act ,[object Object],[object Object],[object Object]
Has the Orphan Drug Act Met It’s Objectives? ,[object Object],[object Object],[object Object],[object Object]
Findings: ,[object Object],[object Object],[object Object],[object Object]
Findings: Total Orphan Designations and Approvals 68 79 67 55 60 56 58 65 56 80 89 75 73 59 33 48 41 1 D E S I G N A T E 14 20 20 19 23 11 11 13 13 12 12 12 11 9 6 7 3 2 A P P R O V A L S 00 99 98 97 96 95 94 93 92 91 90 89 88 87 86 85 84 83 Y E A R
Findings: ,[object Object],[object Object],[object Object],[object Object]
Conclusion: ,[object Object],[object Object],[object Object]
What Does This Mean To You?: Managed Care Vision Today & Beyond ,[object Object],[object Object]
Trends & Concerns (Abroad & Here) ,[object Object],[object Object],[object Object],[object Object]
Trends & Concerns (Abroad & Here) ,[object Object],[object Object],[object Object],[object Object]
Trends & Concerns: Abroad & Here ,[object Object],[object Object],[object Object]
Trends & Concerns: Abroad & Here ,[object Object],[object Object],[object Object],[object Object]
Trends & Concerns: Abroad & Here ,[object Object],[object Object],[object Object],[object Object],[object Object]
Implications ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Implications ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Conclusions ,[object Object],[object Object],[object Object],[object Object],[object Object]

Más contenido relacionado

La actualidad más candente

Orphan Drugs
Orphan DrugsOrphan Drugs
Orphan DrugsANCY JOSE
 
NEW POWER POINT PRESENTATION ON ORPHAN DISEASES AND DRUGS
NEW POWER POINT PRESENTATION ON ORPHAN DISEASES AND DRUGSNEW POWER POINT PRESENTATION ON ORPHAN DISEASES AND DRUGS
NEW POWER POINT PRESENTATION ON ORPHAN DISEASES AND DRUGSManukonda sravani Reddy
 
Regulations for drug approval in USA, E.U & India
Regulations for drug approval in USA, E.U & IndiaRegulations for drug approval in USA, E.U & India
Regulations for drug approval in USA, E.U & IndiaDr. Pankaj Bablani
 
Top Trends in Orphan Drugs
Top Trends in Orphan DrugsTop Trends in Orphan Drugs
Top Trends in Orphan DrugsBill Smith
 
Orphan Drugs – the Challenges and Benefits of Navigating FDA’s Regime Governi...
Orphan Drugs – the Challenges and Benefits of Navigating FDA’s Regime Governi...Orphan Drugs – the Challenges and Benefits of Navigating FDA’s Regime Governi...
Orphan Drugs – the Challenges and Benefits of Navigating FDA’s Regime Governi...Michael Swit
 
Orphan drugs presentation
Orphan drugs presentationOrphan drugs presentation
Orphan drugs presentationAtul Rajpara
 
ISO IDMP: Practical considerations from XEVMPD experience
ISO IDMP: Practical considerations from XEVMPD experienceISO IDMP: Practical considerations from XEVMPD experience
ISO IDMP: Practical considerations from XEVMPD experienceQdossier B.V.
 
EUROPEAN MEDICAL AGENCY
EUROPEAN MEDICAL AGENCYEUROPEAN MEDICAL AGENCY
EUROPEAN MEDICAL AGENCYdatchayani
 
General principles of Periodic Safety Update Reports(PSUR)Psur by Julia Appel...
General principles of Periodic Safety Update Reports(PSUR)Psur by Julia Appel...General principles of Periodic Safety Update Reports(PSUR)Psur by Julia Appel...
General principles of Periodic Safety Update Reports(PSUR)Psur by Julia Appel...László Árvai
 
ORPHAN DRUGS - Dr. Vikram.ppt
ORPHAN DRUGS - Dr.  Vikram.pptORPHAN DRUGS - Dr.  Vikram.ppt
ORPHAN DRUGS - Dr. Vikram.pptVikramSharma288
 
Drug approval process in japan
Drug approval process in japanDrug approval process in japan
Drug approval process in japanManish kumar
 
Safety reporting of a clinical trial
Safety reporting of a clinical trialSafety reporting of a clinical trial
Safety reporting of a clinical trialGOURIPRIYA L S
 
The Investigational New Drug (IND) and New Drug Application (NDA) Process
The Investigational New Drug (IND) and New Drug Application (NDA) ProcessThe Investigational New Drug (IND) and New Drug Application (NDA) Process
The Investigational New Drug (IND) and New Drug Application (NDA) ProcessCarrie O'Connor
 
drug registrastion requirements in china ...sonali mishra
drug registrastion requirements in china  ...sonali mishradrug registrastion requirements in china  ...sonali mishra
drug registrastion requirements in china ...sonali mishraSonaliMishra64
 
Regulatory affairs-Introduction to CTD
Regulatory affairs-Introduction to CTDRegulatory affairs-Introduction to CTD
Regulatory affairs-Introduction to CTDMahesh shinde
 
Clinical Trials in India
Clinical Trials in IndiaClinical Trials in India
Clinical Trials in Indiavaatsalya
 
Abriviated new drug application 505(j) filling
Abriviated new drug application 505(j) fillingAbriviated new drug application 505(j) filling
Abriviated new drug application 505(j) fillingshahnawazQuadir
 
Medical device regulation US, European Union and India
Medical device regulation  US, European Union and IndiaMedical device regulation  US, European Union and India
Medical device regulation US, European Union and IndiaCSIR-URDIP, NCL Campus, Pune
 

La actualidad más candente (20)

Orphan Drugs
Orphan DrugsOrphan Drugs
Orphan Drugs
 
NEW POWER POINT PRESENTATION ON ORPHAN DISEASES AND DRUGS
NEW POWER POINT PRESENTATION ON ORPHAN DISEASES AND DRUGSNEW POWER POINT PRESENTATION ON ORPHAN DISEASES AND DRUGS
NEW POWER POINT PRESENTATION ON ORPHAN DISEASES AND DRUGS
 
Regulations for drug approval in USA, E.U & India
Regulations for drug approval in USA, E.U & IndiaRegulations for drug approval in USA, E.U & India
Regulations for drug approval in USA, E.U & India
 
Top Trends in Orphan Drugs
Top Trends in Orphan DrugsTop Trends in Orphan Drugs
Top Trends in Orphan Drugs
 
Orphan Drugs – the Challenges and Benefits of Navigating FDA’s Regime Governi...
Orphan Drugs – the Challenges and Benefits of Navigating FDA’s Regime Governi...Orphan Drugs – the Challenges and Benefits of Navigating FDA’s Regime Governi...
Orphan Drugs – the Challenges and Benefits of Navigating FDA’s Regime Governi...
 
Orphan drugs presentation
Orphan drugs presentationOrphan drugs presentation
Orphan drugs presentation
 
ISO IDMP: Practical considerations from XEVMPD experience
ISO IDMP: Practical considerations from XEVMPD experienceISO IDMP: Practical considerations from XEVMPD experience
ISO IDMP: Practical considerations from XEVMPD experience
 
Basics Of Pharmacovigilance
Basics Of PharmacovigilanceBasics Of Pharmacovigilance
Basics Of Pharmacovigilance
 
EUROPEAN MEDICAL AGENCY
EUROPEAN MEDICAL AGENCYEUROPEAN MEDICAL AGENCY
EUROPEAN MEDICAL AGENCY
 
General principles of Periodic Safety Update Reports(PSUR)Psur by Julia Appel...
General principles of Periodic Safety Update Reports(PSUR)Psur by Julia Appel...General principles of Periodic Safety Update Reports(PSUR)Psur by Julia Appel...
General principles of Periodic Safety Update Reports(PSUR)Psur by Julia Appel...
 
Orphan drugs development.
Orphan drugs development.Orphan drugs development.
Orphan drugs development.
 
ORPHAN DRUGS - Dr. Vikram.ppt
ORPHAN DRUGS - Dr.  Vikram.pptORPHAN DRUGS - Dr.  Vikram.ppt
ORPHAN DRUGS - Dr. Vikram.ppt
 
Drug approval process in japan
Drug approval process in japanDrug approval process in japan
Drug approval process in japan
 
Safety reporting of a clinical trial
Safety reporting of a clinical trialSafety reporting of a clinical trial
Safety reporting of a clinical trial
 
The Investigational New Drug (IND) and New Drug Application (NDA) Process
The Investigational New Drug (IND) and New Drug Application (NDA) ProcessThe Investigational New Drug (IND) and New Drug Application (NDA) Process
The Investigational New Drug (IND) and New Drug Application (NDA) Process
 
drug registrastion requirements in china ...sonali mishra
drug registrastion requirements in china  ...sonali mishradrug registrastion requirements in china  ...sonali mishra
drug registrastion requirements in china ...sonali mishra
 
Regulatory affairs-Introduction to CTD
Regulatory affairs-Introduction to CTDRegulatory affairs-Introduction to CTD
Regulatory affairs-Introduction to CTD
 
Clinical Trials in India
Clinical Trials in IndiaClinical Trials in India
Clinical Trials in India
 
Abriviated new drug application 505(j) filling
Abriviated new drug application 505(j) fillingAbriviated new drug application 505(j) filling
Abriviated new drug application 505(j) filling
 
Medical device regulation US, European Union and India
Medical device regulation  US, European Union and IndiaMedical device regulation  US, European Union and India
Medical device regulation US, European Union and India
 

Similar a The Orphan Drug Act

The science of hope
The science of hopeThe science of hope
The science of hopeFreedom Monk
 
Ethical Implications of Orphan Drug Research Incentives
Ethical Implications of Orphan Drug Research IncentivesEthical Implications of Orphan Drug Research Incentives
Ethical Implications of Orphan Drug Research IncentivesKuldeep Badoniya
 
Orphan Drug Report
Orphan Drug ReportOrphan Drug Report
Orphan Drug ReportBill Smith
 
Rajasimha-ORDI-RareDiseasePolicy-ODA-Delhi-22Apr2016
Rajasimha-ORDI-RareDiseasePolicy-ODA-Delhi-22Apr2016Rajasimha-ORDI-RareDiseasePolicy-ODA-Delhi-22Apr2016
Rajasimha-ORDI-RareDiseasePolicy-ODA-Delhi-22Apr2016Harsha Rajasimha
 
orphan drugs writeup.doc
orphan drugs writeup.docorphan drugs writeup.doc
orphan drugs writeup.docsuprajakotam
 
Read Logica’s paper on the need for convergence of healthcare and pharma
Read Logica’s paper on the need for convergence of healthcare and pharmaRead Logica’s paper on the need for convergence of healthcare and pharma
Read Logica’s paper on the need for convergence of healthcare and pharmaCGI
 
Orphan Drugs – High Prices: Is there a Way Forward?
Orphan Drugs – High Prices: Is there a Way Forward?Orphan Drugs – High Prices: Is there a Way Forward?
Orphan Drugs – High Prices: Is there a Way Forward?Office of Health Economics
 
Lisman New Paradigms
Lisman New ParadigmsLisman New Paradigms
Lisman New Paradigmsjalisman
 
Health Exchange: Access to medicines April 2010
Health Exchange: Access to medicines April 2010Health Exchange: Access to medicines April 2010
Health Exchange: Access to medicines April 2010HealthlinkWorldwide
 
Development of drugs in public-private partnership (PPP) environments
Development of drugs in  public-private partnership (PPP) environmentsDevelopment of drugs in  public-private partnership (PPP) environments
Development of drugs in public-private partnership (PPP) environmentspmaugeri
 
Clinical Trials In Developing Countries Unethical Practice Or A Product Of N...
Clinical Trials In Developing Countries  Unethical Practice Or A Product Of N...Clinical Trials In Developing Countries  Unethical Practice Or A Product Of N...
Clinical Trials In Developing Countries Unethical Practice Or A Product Of N...Dr Aneek Gupta
 
Zweig powerpoint on Palliative Care in Nursing Homes for Theme Session co-spo...
Zweig powerpoint on Palliative Care in Nursing Homes for Theme Session co-spo...Zweig powerpoint on Palliative Care in Nursing Homes for Theme Session co-spo...
Zweig powerpoint on Palliative Care in Nursing Homes for Theme Session co-spo...MedicineAndHealthUSA
 
The High Prices of Prescription Drugs Increase Costs for Everyone
The High Prices of Prescription Drugs Increase Costs for EveryoneThe High Prices of Prescription Drugs Increase Costs for Everyone
The High Prices of Prescription Drugs Increase Costs for EveryoneAmerica's Health Insurance Plans
 
Proper prescribing module1_revised v2
Proper prescribing module1_revised v2Proper prescribing module1_revised v2
Proper prescribing module1_revised v2bahlinnm
 
Demonstrating Significant Benefit for an OMP
Demonstrating Significant Benefit for an OMPDemonstrating Significant Benefit for an OMP
Demonstrating Significant Benefit for an OMPMauro Placchi
 
RF 2016 07 Health Technology Assessment
RF 2016 07 Health Technology AssessmentRF 2016 07 Health Technology Assessment
RF 2016 07 Health Technology AssessmentRichard Phillips
 

Similar a The Orphan Drug Act (20)

The science of hope
The science of hopeThe science of hope
The science of hope
 
Ethical Implications of Orphan Drug Research Incentives
Ethical Implications of Orphan Drug Research IncentivesEthical Implications of Orphan Drug Research Incentives
Ethical Implications of Orphan Drug Research Incentives
 
MMHA 6135 WK 5 App
MMHA 6135 WK 5 AppMMHA 6135 WK 5 App
MMHA 6135 WK 5 App
 
Orphan Drug Report
Orphan Drug ReportOrphan Drug Report
Orphan Drug Report
 
Rajasimha-ORDI-RareDiseasePolicy-ODA-Delhi-22Apr2016
Rajasimha-ORDI-RareDiseasePolicy-ODA-Delhi-22Apr2016Rajasimha-ORDI-RareDiseasePolicy-ODA-Delhi-22Apr2016
Rajasimha-ORDI-RareDiseasePolicy-ODA-Delhi-22Apr2016
 
orphan drugs writeup.doc
orphan drugs writeup.docorphan drugs writeup.doc
orphan drugs writeup.doc
 
Read Logica’s paper on the need for convergence of healthcare and pharma
Read Logica’s paper on the need for convergence of healthcare and pharmaRead Logica’s paper on the need for convergence of healthcare and pharma
Read Logica’s paper on the need for convergence of healthcare and pharma
 
Orphan Drugs – High Prices: Is there a Way Forward?
Orphan Drugs – High Prices: Is there a Way Forward?Orphan Drugs – High Prices: Is there a Way Forward?
Orphan Drugs – High Prices: Is there a Way Forward?
 
Lisman New Paradigms
Lisman New ParadigmsLisman New Paradigms
Lisman New Paradigms
 
Health Exchange: Access to medicines April 2010
Health Exchange: Access to medicines April 2010Health Exchange: Access to medicines April 2010
Health Exchange: Access to medicines April 2010
 
Consumer health: time for a regulatory re-think?
Consumer health: time for a regulatory re-think?Consumer health: time for a regulatory re-think?
Consumer health: time for a regulatory re-think?
 
Twillman preventing rx abuse
Twillman preventing rx abuseTwillman preventing rx abuse
Twillman preventing rx abuse
 
Development of drugs in public-private partnership (PPP) environments
Development of drugs in  public-private partnership (PPP) environmentsDevelopment of drugs in  public-private partnership (PPP) environments
Development of drugs in public-private partnership (PPP) environments
 
Clinical Trials In Developing Countries Unethical Practice Or A Product Of N...
Clinical Trials In Developing Countries  Unethical Practice Or A Product Of N...Clinical Trials In Developing Countries  Unethical Practice Or A Product Of N...
Clinical Trials In Developing Countries Unethical Practice Or A Product Of N...
 
Zweig powerpoint on Palliative Care in Nursing Homes for Theme Session co-spo...
Zweig powerpoint on Palliative Care in Nursing Homes for Theme Session co-spo...Zweig powerpoint on Palliative Care in Nursing Homes for Theme Session co-spo...
Zweig powerpoint on Palliative Care in Nursing Homes for Theme Session co-spo...
 
The High Prices of Prescription Drugs Increase Costs for Everyone
The High Prices of Prescription Drugs Increase Costs for EveryoneThe High Prices of Prescription Drugs Increase Costs for Everyone
The High Prices of Prescription Drugs Increase Costs for Everyone
 
Proper prescribing module1_revised v2
Proper prescribing module1_revised v2Proper prescribing module1_revised v2
Proper prescribing module1_revised v2
 
Demonstrating Significant Benefit for an OMP
Demonstrating Significant Benefit for an OMPDemonstrating Significant Benefit for an OMP
Demonstrating Significant Benefit for an OMP
 
RF 2016 07 Health Technology Assessment
RF 2016 07 Health Technology AssessmentRF 2016 07 Health Technology Assessment
RF 2016 07 Health Technology Assessment
 
Directed Project
Directed ProjectDirected Project
Directed Project
 

The Orphan Drug Act

  • 1. The Orphan Drug Act Jeff W. Bailey MS Senior Regional Business Manager Shire Human Genetic Therapies June 2009
  • 2.
  • 3.
  • 4.
  • 5.
  • 6.
  • 7.
  • 8.
  • 9. Findings: Total Orphan Designations and Approvals 68 79 67 55 60 56 58 65 56 80 89 75 73 59 33 48 41 1 D E S I G N A T E 14 20 20 19 23 11 11 13 13 12 12 12 11 9 6 7 3 2 A P P R O V A L S 00 99 98 97 96 95 94 93 92 91 90 89 88 87 86 85 84 83 Y E A R
  • 10.
  • 11.
  • 12.
  • 13.
  • 14.
  • 15.
  • 16.
  • 17.
  • 18.
  • 19.
  • 20.